Thiomyristoyl

Thiomyristoyl
Clinical data
Drug class	Sirtuin 2 (SIRT2) inhibitor
Identifiers
	IUPAC name benzyl N-[(2S)-1-anilino-1-oxo-6-(tetradecanethioylamino)hexan-2-yl]carbamate;
CAS Number	1429749-41-6;
PubChem CID	126843233;
ChemSpider	58843468;
ChEMBL	ChEMBL4129995;
Chemical and physical data
Formula	C34H51N3O3S
Molar mass	581.86 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCCCCCCCCCCC(=S)NCCCC[C@@H](C(=O)NC1=CC=CC=C1)NC(=O)OCC2=CC=CC=C2;
	InChI InChI=1S/C34H51N3O3S/c1-2-3-4-5-6-7-8-9-10-11-18-26-32(41)35-27-20-19-25-31(33(38)36-30-23-16-13-17-24-30)37-34(39)40-28-29-21-14-12-15-22-29/h12-17,21-24,31H,2-11,18-20,25-28H2,1H3,(H,35,41)(H,36,38)(H,37,39)/t31-/m0/s1; Key:CJQGLLUJIVNREL-HKBQPEDESA-N;

Thiomyristoyl is a drug which acts as a potent sirtuin 2 (SIRT2) inhibitor. It inhibits SIRT2 with an IC₅₀ of 28 nM, though its activity at other SIRT subtypes has not been well characterized. It has beneficial effects in an animal model of ulcerative colitis,^[1] and is also used for studying the role of SIRT2 in cancer progression.^[2]^[3]

References

^ Xu Y, Cai R, Zhao Z, Zhou L, Zhou Q, Hassan S, et al. (January 2021). "Thiomyristoyl ameliorates colitis by blocking the differentiation of Th17 cells and inhibiting SIRT2-induced metabolic reprogramming". International Immunopharmacology. 90 107212. doi:10.1016/j.intimp.2020.107212. PMID 33310666.
^ Xu L, Wang L, Zhou L, Dorfman RG, Pan Y, Tang D, et al. (May 2019). "The SIRT2/cMYC Pathway Inhibits Peroxidation-Related Apoptosis In Cholangiocarcinoma Through Metabolic Reprogramming". Neoplasia. 21 (5): 429–441. doi:10.1016/j.neo.2019.03.002. PMC 6441712. PMID 30933885.
^ Lin R, Yang Y, Wu E, Zhou M, Wang S, Zhang Q (January 2023). "SIRT2 promotes cell proliferation and migration through mediating ERK1/2 activation and lactosylceramide accumulation in prostate cancer". The Prostate. 83 (1): 71–81. doi:10.1002/pros.24437. PMID 36082450.

[1] Xu Y, Cai R, Zhao Z, Zhou L, Zhou Q, Hassan S, et al. (January 2021). "Thiomyristoyl ameliorates colitis by blocking the differentiation of Th17 cells and inhibiting SIRT2-induced metabolic reprogramming". International Immunopharmacology. 90 107212. doi:10.1016/j.intimp.2020.107212. PMID 33310666.

[2] Xu L, Wang L, Zhou L, Dorfman RG, Pan Y, Tang D, et al. (May 2019). "The SIRT2/cMYC Pathway Inhibits Peroxidation-Related Apoptosis In Cholangiocarcinoma Through Metabolic Reprogramming". Neoplasia. 21 (5): 429–441. doi:10.1016/j.neo.2019.03.002. PMC 6441712. PMID 30933885.

[3] Lin R, Yang Y, Wu E, Zhou M, Wang S, Zhang Q (January 2023). "SIRT2 promotes cell proliferation and migration through mediating ERK1/2 activation and lactosylceramide accumulation in prostate cancer". The Prostate. 83 (1): 71–81. doi:10.1002/pros.24437. PMID 36082450.

[1]

[2]

[3]

See also

References